Phenylalanine ammonia lyase Inhibitors
1 drugsAbout Phenylalanine ammonia lyase
Phenylalanine ammonia lyase (PAL) catalyzes the first step in the phenylpropanoid pathway in plants, bacteria, and fungi. It modulates phenylalanine levels in the body by catalyzing the conversion of phenylalanine to ammonia and trans-cinnamic acid.
PAL is a therapeutic target for managing phenylalanine levels, relevant in specific metabolic disorders. There is currently no genetic evidence data available linking PAL mutations directly to disease susceptibility.
PALYNZIQ is the only FDA-approved drug targeting PAL, a biologic used to manage a specific metabolic disorder. BIOMARIN PHARM is the sole company with an approved drug for this target.
Top Phenylalanine ammonia lyase Drugs
BIOMARIN PHARM is the only company with an approved drug targeting PAL.
High market concentration indicates potential entry barriers; consider strategic partnerships or niche indications.
Phenylalanine ammonia lyase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Phenylalanine ammonia lyase, using biologic (other) modality.
Explore small molecule or alternative modalities to differentiate from existing therapies and expand market reach.
Phenylalanine ammonia lyase Clinical Trials 4 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Phenylalanine ammonia lyase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phenylalanine ammonia lyase Drug Approval Timeline (2018 - 2018)
The first and most recent drug approval for PAL was PALYNZIQ in 2018.
The single approval suggests an immature market; further research may uncover new therapeutic applications.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Phenylalanine ammonia lyase. A trial counts if an approved drug acting on Phenylalanine ammonia lyase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.